Low-dose CBD for 4 weeks did not improve blood sugar control or gut bacteria in overweight adults
Daily 60mg CBD for 4 weeks did not improve glucose tolerance, modify the gut microbiome, or reduce inflammation in sedentary overweight or obese adults compared to placebo.
Quick Facts
What This Study Found
CBD (30mg every 12 hours for 4 weeks) showed no significant effect on glucose tolerance (Matsuda Index), gut microbiome composition, or inflammatory markers compared to placebo in 16 adults with overweight or obesity.
Key Numbers
16 participants. CBD dose: 30mg every 12 hours (60mg/day). Duration: 4 weeks. Matsuda Index (insulin sensitivity): no significant change (p>0.05). Gut microbiome: no appreciable changes. Inflammation: no modification.
How They Did This
Randomized, double-blind, parallel design pilot study with 16 adults (6 males, 10 females) taking either placebo or CBD 30mg twice daily for 4 weeks, with oral glucose tolerance tests and fecal microbiome analysis at baseline and post-intervention.
Why This Research Matters
Epidemiological data link cannabis use to lower diabetes rates, and animal studies suggested CBD might improve glucose tolerance through gut microbiome changes. This pilot finds no such effect at low doses in humans.
The Bigger Picture
The cannabis-diabetes paradox seen in population studies may not be explained by CBD specifically, or may require higher doses or longer exposure. Other cannabinoids or the full plant may be responsible for the epidemiological association.
What This Study Doesn't Tell Us
Very small sample (16 participants). Low CBD dose (60mg/day) may be insufficient. Short duration (4 weeks) may not allow metabolic changes to manifest. Sedentary overweight adults may not be the optimal population.
Questions This Raises
- ?Would higher CBD doses or longer treatment show effects?
- ?Is the cannabis-diabetes link driven by THC or other cannabinoids rather than CBD?
- ?Would physically active users show different results?
Trust & Context
- Key Stat:
- 60mg/day CBD for 4 weeks: no effect on glucose tolerance, gut, or inflammation
- Evidence Grade:
- Well-designed double-blind RCT but severely underpowered with only 16 participants. Low dose and short duration further limit conclusions.
- Study Age:
- Published in 2025.
- Original Title:
- Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.
- Published In:
- Cannabis and cannabinoid research (2025)
- Authors:
- Ewell, Taylor R, Bomar, Matthew C, Abbotts, Kieran S S, Kayne, Brendan T, Risk, Briana D, Williams, Natasha N B, Wei, Yuren, Dooley, Gregory P, Weir, Tiffany L, Bell, Christopher
- Database ID:
- RTHC-06423
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does CBD help with blood sugar control?
In this small pilot study, 60mg/day of CBD for 4 weeks did not improve glucose tolerance in overweight or obese adults. The researchers suggest CBD alone may not explain the lower diabetes rates seen in cannabis users.
Does CBD change gut bacteria?
Not at the dose tested. Four weeks of 60mg/day CBD did not appreciably modify the gut microbiome in this pilot study, despite animal research suggesting such effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06423APA
Ewell, Taylor R; Bomar, Matthew C; Abbotts, Kieran S S; Kayne, Brendan T; Risk, Briana D; Williams, Natasha N B; Wei, Yuren; Dooley, Gregory P; Weir, Tiffany L; Bell, Christopher. (2025). Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.. Cannabis and cannabinoid research. https://doi.org/10.1177/25785125251391085
MLA
Ewell, Taylor R, et al. "Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.." Cannabis and cannabinoid research, 2025. https://doi.org/10.1177/25785125251391085
RethinkTHC
RethinkTHC Research Database. "Short-Term Low Dose Cannabidiol Does Not Influence Glucose T..." RTHC-06423. Retrieved from https://rethinkthc.com/research/ewell-2025-shortterm-low-dose-cannabidiol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.